LONDON — GlaxoSmithKline PLC said Monday it had reached a deal with Indian drug developer Dr. Reddy’s Laboratories Ltd. to develop and market selected products across many emerging markets. London-based Glaxo did not reveal terms of the deal, which is effective immediately but excludes India. Under the agreement, Glaxo will gain exclusive access to Dr. Reddy’s portfolio and future pipeline of more than 100 branded pharmaceuticals in fast growing therapeutic segments such as cardiovascular, diabetes, oncology, gastroenterology and pain management. The products will be manufactured by Dr. Reddy’s and licensed and supplied by Glaxo in various countries in Africa, the Middle East, Asia Pacific and Latin America. In some markets, products will be co-marketed by Glaxo and Dr. Reddy’s. Revenues will be reported by Glaxo, and shared with Dr. Reddy’s, Glaxo said. “This is another significant step forward in our strategy to grow and diversify GSK’s business in emerging markets,” said Abbas Hussain, president for emerging markets at GlaxoSmithKline. “Growth in both population and economic prosperity is leading to increased demand for branded pharmaceuticals.”
